Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$49.14 USD
+0.21 (0.43%)
Updated Apr 22, 2024 04:00 PM ET
After-Market: $49.15 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth F Momentum C VGM
Company Summary
New York-based Bristol-Myers Squibb is one of the leading global specialty biopharmaceutical companies focused on developing treatments targeting severe diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio of drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has essential immunology and cardiovascular drugs like Orencia and Eliquis, diversifying its portfolio. Notably, in the cardiovascular space, Eliquis is now the leading global oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market while advancing its Factor XIa inhibitor program.
...
Company Summary
New York-based Bristol-Myers Squibb is one of the leading global specialty biopharmaceutical companies focused on developing treatments targeting severe diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio of drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has essential immunology and cardiovascular drugs like Orencia and Eliquis, diversifying its portfolio. Notably, in the cardiovascular space, Eliquis is now the leading global oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market while advancing its Factor XIa inhibitor program.
The acquisition of Celgene Corporation for $74 billion in November 2019 has strengthened and added Revlimid to its portfolio. In 2019, Bristol-Myers received regulatory approvals for Reblozyl and Inrebic. In November 2020, Bristol-Myers acquired MyoKardia for approximately $13.1 billion. The company also acquired Turning Point Therapeutics. These acquisitions facilitate the company’s efforts to diversify its revenue base.
In January 2024, Bristol Myers acquired Mirati Therapeutics for $58.00 per share in cash, amounting to a total equity value of $4.8 billion. The acquisition added the approved lung cancer drug Krazati to the company’s oncology portfolio. In February 2024, Bristol Myers acquired the radiopharmaceutical therapeutics (RPT) company RayzeBio, Inc. for $4.1 billion, adding a differentiated actinium-based radiopharmaceutical platform. In March 2024, Bristol Myers acquired Karuna Therapeutics, Inc. for $330.00 per share in cash for a total equity value of $14 billion to strengthen its neuroscience portfolio. Karuna is focused on developing drugs for psychiatric and neurological conditions.
Bristol-Myers reported revenues of $45 billion in 2023, down 22% from the 2022 level. Eliquis and Opdivo sales came in at $12.2 billion and $9 billion, respectively. Revlimid sales came in at $6.1 billion.
General Information
Bristol Myers Squibb Company
ROUTE 206 AND PROVINCE LINE ROAD
PRINCETON, NJ 08543
Phone: 609-252-4621
Fax: 212-546-4020
Web: http://www.bms.com
Email: investor.relations@bms.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 3/31/2024 |
Earnings Date | 4/25/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -4.51 |
Current Year EPS Consensus Estimate | 0.66 |
Estimated Long-Term EPS Growth Rate | 5.00 |
Earnings Date | 4/25/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 48.93 |
52 Week High | 70.94 |
52 Week Low | 47.58 |
Beta | 0.39 |
20 Day Moving Average | 10,717,154.00 |
Target Price Consensus | 56.32 |
4 Week | -5.78 |
12 Week | -1.55 |
YTD | -4.64 |
4 Week | -0.71 |
12 Week | -3.06 |
YTD | -8.43 |
Shares Outstanding (millions) | 2,026.76 |
Market Capitalization (millions) | 99,169.30 |
Short Ratio | NA |
Last Split Date | 3/1/1999 |
Dividend Yield | 4.91% |
Annual Dividend | $2.40 |
Payout Ratio | 0.30 |
Change in Payout Ratio | -0.01 |
Last Dividend Payout / Amount | 4/4/2024 / $0.60 |
Fundamental Ratios
P/E (F1) | 74.70 |
Trailing 12 Months | 6.52 |
PEG Ratio | 14.94 |
vs. Previous Year | -6.59% |
vs. Previous Quarter | -15.00% |
vs. Previous Year | 0.62% |
vs. Previous Quarter | 4.66% |
Price/Book | 3.38 |
Price/Cash Flow | 3.93 |
Price / Sales | 2.20 |
3/31/24 | NA |
12/31/23 | 50.95 |
9/30/23 | 51.59 |
3/31/24 | NA |
12/31/23 | 16.67 |
9/30/23 | 17.03 |
3/31/24 | NA |
12/31/23 | 1.43 |
9/30/23 | 1.18 |
3/31/24 | NA |
12/31/23 | 1.31 |
9/30/23 | 1.07 |
3/31/24 | NA |
12/31/23 | 34.66 |
9/30/23 | 35.62 |
3/31/24 | NA |
12/31/23 | 17.83 |
9/30/23 | 18.44 |
3/31/24 | NA |
12/31/23 | 18.75 |
9/30/23 | 19.19 |
3/31/24 | NA |
12/31/23 | 14.49 |
9/30/23 | 14.28 |
3/31/24 | NA |
12/31/23 | 4.25 |
9/30/23 | 4.33 |
3/31/24 | NA |
12/31/23 | 1.24 |
9/30/23 | 1.11 |
3/31/24 | NA |
12/31/23 | 55.42 |
9/30/23 | 52.51 |